Fats and atheroma.

Mann, J I

doi:10.1136/bmj.1.6172.1214

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from the two articles already mentioned, many other studies have indicated that cholesterol-lowering agents such as oestrogens and Clofibrate are of no value in the treatment of myocardial infarction (Oliver and Boyd, 1961 ;Marmorston et al, 1962;Coronary Drug Project Group, 1975). Indeed McMichael (1979) concluded that medical endorsement of cholesterol-reducing measures should be withdrawn although this assertion has been challenged by Mann (1979).…”

Section: Discussionmentioning

confidence: 99%

The Effect of Various Regimens of Hormone Therapy on Serum Cholesterol and Triglyceride Concentrations in Postmenopausal Women

Paterson

Sturdee

Moore

et al. 1980

BJOG

View full text Add to dashboard Cite

Summary The serum cholesterol and triglyceride concentrations of 84 postmenopausal women both before and after 2, 6 and 12 months therapy with various regimens of hormone therapy were measured. There was little alteration in mean serum cholesterol concentration with cyclical oestrogens but both sequential mestranol and norethisterone and sequential oestradiol valerate and norgestrel significantly reduced the mean serum cholesterol concentration to a level similar to that found in age‐matched premenopausal women. There was a small and sometimes significant rise in serum triglyceride concentration with cyclical oestrogens. Sequential mestranol and norethisterone significantly elevated serum triglyceride levels, but sequential oestradiol valerate and norgestrel significantly depressed them. The results suggest that the progestogenic agent norgestrel has an important role to play in reducing both serum cholesterol and triglyceride levels, and that the sequential preparations, by virtue of their greater cholesterol lowering effect, should perhaps be preferred to cyclical oestrogens.

show abstract